The world is “on the cusp” of a brand new drug remedy for Alzheimer’s that would free hundreds of thousands from the worry and heartbreak dementia brings.

A “very exciting” antibody medicine has been confirmed to sluggish the ­illness by greater than a 3rd in these sufferers who present early signs.

It is the second drug in lower than a yr that has been discovered to delay development following a long time of failed therapies – and heralds a brand new period in dementia care.

Dr Susan Kohlhaas, of Alzheimer’s Research UK, mentioned: “This is incredibly encouraging and another hugely significant moment for dementia research.

“We’re now on the cusp of a first generation of treatments for Alzheimer’s disease, something that many thought impossible only a decade ago.

READ MORE: Middle-aged people told using internet regularly will lower risk of dementia by half

“People should be really encouraged by this news, which is yet more proof that research can take us ever closer towards a cure.”

The drug donanemab, made by US pharma large Lilly, stimulates the immune system to destroy poisonous ­proteins within the mind which might be believed to trigger dementia. It is given by ­intravenous infusion as soon as a month for as much as 18 months.

Donanemab was utilized in a trial ­of 1,182 individuals with early-stage Alzheimer’s and intermediate ranges of tau protein. After a yr, 47 % of these on the drug had not seen the illness progress, in contrast with 29 % of these taking a placebo.

Researchers calculated that after 18 months the drug had slowed sufferers’ decline by 35 % on common. The discount of their skill to carry out widespread each day actions was 40 % lower than beforehand.

Some 552 individuals with extra superior signs and excessive tau ­ranges, that are more durable to deal with, additionally joined the research. When they have been included within the evaluation, the drug slowed decline by 22 % total.

Dr Eric Reiman, govt director of the Banner Alzheimer’s Institute within the US, known as the outcomes “very exciting”. There have been some side-effects together with swelling of the mind.

Lilly mentioned most of these have been “mild to moderate” however three sufferers died. Some 31 % of sufferers receiving donanemab skilled small mind bleeds, as did 14 % of these within the placebo group.

Dr Kohlhaas, govt director of analysis at Alzheimer’s Research UK, mentioned: “The treatment effect is modest, as is the case for many first-generation drugs, and there are risks of serious side effects that need to be fully scrutinised before donanemab can be marketed. However, this news underlines the urgency of preparing the NHS to make these treatments available should regulators deem them safe.”

Scientists are desperate to see the complete trial outcomes, which can be given on the Alzheimer’s Association International Conference in Amsterdam in July. The success of donanemab follows good outcomes for lecanemab: in September it turned the primary drug confirmed to sluggish Alzheimer’s, by round 27 %.

Dr Richard Oakley, of Alzheimer’s Society, mentioned: “We now have two potential new drugs in just 12 months – and for the first time, drugs that seem to slow the progression of ­the disease. This could be the beginning of the end of Alzheimer’s.”

Lilly mentioned it could search regulatory approval for donanemab internationally “as quickly as possible”.

If authorized within the UK, it's prone to be pricey and medicines assessors will decide how cost-effective it's. Experts urged the NHS to enhance analysis programs so sufferers who will profit might be recognized simply.

Dr Charles Marshall, neurologist at Queen Mary University of London, mentioned specialists would calculate “the risks and benefits” as soon as full outcomes are printed: “This will inform ­decisions about whether donanemab should be routinely given.”